^
    Apply
    A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation (NCT05756153)
    Phase 1/2
    Zhejiang Genfleet Therapeutics Co., Ltd.
    Recruiting
    Last update posted :
    03/11/2024
    Initiation :
    04/25/2023
    Primary completion :
    03/01/2025
    Completion :
    08/01/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • Dupert (fulzerasib)
    A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations (NCT05005234)
    Phase 1/2
    Innovent Biologics (Suzhou) Co. Ltd.
    Recruiting
    Last update posted :
    08/16/2023
    Initiation :
    09/10/2021
    Primary completion :
    01/10/2024
    Completion :
    04/10/2024
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Dupert (fulzerasib)
    Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation (NCT05504278)
    Phase 1
    Innovent Biologics (Suzhou) Co. Ltd.
    Recruiting
    Last update posted :
    05/29/2023
    Initiation :
    09/20/2022
    Primary completion :
    05/12/2024
    Completion :
    07/31/2027
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • carboplatin • Tyvyt (sintilimab) • pemetrexed • Dupert (fulzerasib)
    A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer (NCT05497336)
    Phase 1
    Innovent Biologics (Suzhou) Co. Ltd.
    Recruiting
    Last update posted :
    09/30/2022
    Initiation :
    08/18/2022
    Primary completion :
    08/30/2023
    Completion :
    09/30/2024
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • Dupert (fulzerasib)